P028: Switching treatment to cipaglucosidase alfa+miglustat positively affects motor function and quality of life in patients with late-onset Pompe disease

• Priya Kishnani,
• Barry Byrne,
• Kristl Claeys,
• Paula Clemens,
• Jordi Díaz-Manera,
• Mazen Dimachkie,
• Hani Kushlaf,
• Tahseen Mozaffar,
• Mark Roberts,
• Antonio Toscano,
• Noemi Hummel,
• Fred Holdbrook,
• Simon Shohet,
• Benedikt Schoser

Affiliations

Priya Kishnani

Duke University Medical Center, Durham, NC

Barry Byrne

University of Florida, Gainesville, FL

Kristl Claeys

Department of Neurology, University Hospitals Leuven, Leuven, Belgium

Paula Clemens

Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA

Jordi Díaz-Manera

John Walton Muscular Dystrophy Research Centre, Newcastle University, Newcastle upon Tyne, UK

Mazen Dimachkie

Department of Neurology, University of Kansas Medical Center, Kansas City, KS

Hani Kushlaf

University of Cincinnati, Cincinnati, OH

Tahseen Mozaffar

Department of Neurology, University of California, Irvine, CA

Mark Roberts

Salford Royal NHS Foundation Trust, Salford, UK

Antonio Toscano

ERN-NMD Center for Neuromuscular Disorders, University of Messina, Messina, Italy

Noemi Hummel

Certara GmbH, Lörrach, Germany

Fred Holdbrook

Amicus Therapeutics, Inc., Princeton, NJ

Simon Shohet

Amicus Therapeutics Ltd, Marlow, UK

Benedikt Schoser

Friedrich-Baur-Institute at Department of Neurology, LMU University Hospital, LMU Munich, Germany